A cost analysis of nearly 30,000 anti-VEGF visits found travel and missed work, not drug price, drive most of patients' out-of-pocket burden.

EHR-based risk calculator reduces 3-year diabetes risk in patients with prediabetes ...

A randomized, open-label comparison in 31 children (mostly cerebral palsy) evaluated VR plus nitrous oxide versus standard distraction approaches during botulinum toxin injections. Pain scores ...

Net specialty spend reached $1,251 PMPY in 2025, driven primarily by rising utilization and member penetration, rather than ...

CMS will terminate the Part D premium stabilization subsidies for standalone PDPs in 2027, citing mature sponsor pricing under IRA benefit redesign and a return to “traditional market conditions.” ...

Questions about price and access hover over the positive results for a weekly HIV treatment pill that combines Merck’s islatravir and Gilead’s lenacapavir. Prospects for a weekly pill for HIV ...

Raphael J. Landovitz, M.D., says rare lenacapavir breakthrough infections raise new questions about how often patients need testing between PrEP doses. Rare breakthrough HIV infections in people ...

Require each hospital and care provider to post a single commercial (private insurance) price for each care location, expressed as a simple multiple of the price Medicare pays.

CAPTIVATE observed zero HIV acquisitions with CAB LA PrEP, alongside 98% persistence and robust on-time dosing (92% for second initiation injections; 82% for continuation injections). Switching ...

Open-label data reinforced lenacapavir’s prevention profile, with zero infections on open-label lenacapavir in PURPOSE 1 and one infection in PURPOSE 2. Extension participation was robust, with ~95% ...

Simtriyo’s mechanism combines norepinephrine/dopamine augmentation with serotonin modulation, expanding beyond traditional stimulant and selective nonstimulant approaches for heterogeneous ADHD ...